Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Borneol/cilostazol - NeuroDawn Pharmaceutical

Next Previous
Drug Profile

Borneol/cilostazol - NeuroDawn Pharmaceutical

Alternative Names: Cilostazol dexborneol - NeuroDawn Pharmaceutical; cilostazol/borneol - NeuroDawn Pharmaceutical; cilostazol/dexborneol - NeuroDawn Pharmaceuticals; d-borneol/cilostazol - NeuroDawn Pharmaceuticals; Y 6; Y-6 sublingual tablet

Latest Information Update: 10 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroDawn
  • Class Anti-inflammatories; Antiplatelets; Antiseptics; Antispasmodics; Heterocyclic bicyclo compounds; Neuroprotectants; Nootropics; Quinolines; Small molecules; Terpenes; Tetrazoles; Traditional Chinese medicine; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stroke
  • Preclinical Cognition disorders

Most Recent Events

  • 19 Jun 2025 Beijing Tiantan Hospital in collaboration with Neurodawn Pharmaceutical plans a phase III FUTURE-2 trial for Ischaemic stroke(PO, Tablet) in August 2025 (NCT07040085)
  • 14 Nov 2023 NeuroDawn Pharmaceuticals plans a phase II FUTURE trial for Stroke (In adults, In the elderly) (Sublingual, Tablet) in November 2023 (NCT06138834)
  • 04 Aug 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top